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A phase II study of the insulin-like growth factor type I 
receptor inhibitor IMC-A12 in patients with metastatic  
uveal melanoma
Jane Matteia,*, Alexej Ballhausena,e,*, Roland Bassettb,  
Michael Shepharda, Chandrani Chattopadhyaya, Courtney Hudgensc,  
Michael Tetzlaffc, Scott Woodmana,d, Takami Satof and Sapna P. Patela     
Uveal melanoma is a rare and aggressive malignancy and 
up to half of all patients will develop metastatic disease 
despite the effective treatment of the primary tumor. 
Insulin-like growth factors I/II play a fundamental role 
in the cell migration, proliferation, and apoptosis. IMC-
A12, a mAb specifically targets insulin-like growth factor 
type I receptor, has shown promise in preclinical studies. 
We performed a multicenter phase II study for patients 
with metastatic uveal melanoma administered IMC-A12 
10 mg/kg IV every two weeks until disease progression or 
unacceptable toxicity. The primary endpoint was objective 
response (proportion of patients with complete or partial 
response), and secondary endpoints were disease control 
rate, progression-free survival, and overall survival. A 
total of 18 patients enrolled in this study (10 males and 
eight females) with a median age. Ten patients (55%) had 
stable disease, seven patients (38%) had progression as 
best overall response. No partial response or complete 
response was observed; however, the disease control 
rate, defined as complete response + partial response + 
stable disease ≥3 months, was 50%. Median progression-
free survival was 3.1 months, and median overall survival 
was 13.8 months. Adverse events of any grade occurred 
in 13 patients (72.2%). Treatment-related grade 3 adverse 
events were rare, and there were no grade 4 or 5 related 
adverse events. IMC-A12 was very well tolerated, however, 
showed limited clinical activity in uveal melanoma as 
a single agent. Due to its low toxicity profile it could 
be studied in combination with other pathway-specific 
agents. Melanoma Res 30: 574–579 Copyright © 2020 The 
Author(s). Published by Wolters Kluwer Health, Inc.
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Background
Uveal melanoma is the most common primary intraoc-
ular malignant tumor in adults and the second most 
common type of primary malignant melanoma in the 
body. Although metastatic disease is rare at the time of 
diagnosis, approximately 50% of patients will eventually 
develop distant disease, despite definitive treatment for 
their primary uveal melanoma with brachytherapy, enu-
cleation, or proton beam radiation. Most commonly, met-
astatic disease develops through vascular spread to the 
liver, which accounts for 95% of metastatic cases. Patients 
who develop distant disease have a poor prognosis and 
despite therapy, their median survival is six to seven 
months with a dismal one-year survival of approximately 
10–15%. Locoregional treatment options for metastatic 
disease include local surgical resection, radiofrequency 
ablation, or chemoembolization [1,2]. Systemic chemo-
therapy has failed to show any significant efficacy against 
metastatic uveal melanoma. Retrospective reviews from 
MD Anderson Cancer Center, Eastern Cooperative 
Oncology Group and Southwest Oncology Group indi-
cated that patients with uveal melanoma (especially 
those with liver metastasis) rarely responded to drugs 
commonly used for the treatment of metastatic cutane-
ous/mucosal melanoma [2,3].
So far, no specific targeted therapies have proven activity 
in uveal melanoma, but preclinical studies suggest poten-
tial benefit of inhibitors of c-mesenchymal to epithelial 
transition (c-Met), sarcoma (SRC), rat sarcoma (Ras), 
epidermal growth factor receptor (EGFR), and vascu-
lar endothelial growth factor (VEGF) receptor tyrosine 
kinases, phosphatidylinositol-3-kinase-AKT pathways, 
and receptor tyrosine kinases and insulin-like growth 
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factor type I receptor (IGF-1R) [4,5]. IGF-1R is a mem-
ber of the insulin receptor family and is activated through 
binding of two high-affinity ligands [6]. While insulin 
receptor substrate-1 (IGF-1) is believed to mediate the 
mutagenic effects of IGF-1R, insulin receptor substrate-2 
(IGF-2) is believed to play a role in metabolic and prolif-
erative signals triggered by the insulin receptors. Primary 
pathways involved in IGF transduction are the phosphati-
dylinositol 3-kinase/Akt and mitogen-activated protein 
kinase pathways [7,8].
IMC-A12 or Cixutuxumab (Imclone, Inc.) is a recom-
binant human IgG1 mAb which specifically targets the 
human IGF-1R and antagonizes IGF-1 and IGF-2 ligand 
binding and signaling, while it does not bind or recognize 
the human insulin receptor [9,10]. In addition, binding of 
IMC-A12 to IGF-1R leads to internalization and degra-
dation of the receptor. IMC-A12 inhibits the proliferation 
and growth of a variety of human tumor cell lines, both in 
vitro and in vivo [2].
In two phase I studies, IMC-A12 was evaluated for safety 
and antitumor effects either weekly (CP13-0501; total of 
24 patients enrolled) or every other week (CP13-0502; 
total of 16 patients enrolled) at doses ranging from 3 mg/
kg through 27 mg/kg. Common adverse event included 
hyperglycemia, while severe adverse events occurred 
infrequently. No maximum tolerated dose was identified. 
Dosing with ≥6 mg/kg weekly and ≥10 mg/kg every-2-
week, predetermined target serum minimum concentra-
tions (60 μg/mL) were achieved. Overall, stable disease 
was the best response in 25% of all patients.
IGF-1R expression has been shown to significantly cor-
relate with worse prognosis in uveal melanoma patients 
[4,11,12]. We hypothesized that this increased mortality 
rate may be due to Akt activation through the IGF-1 
pathway. Thus, targeting IGF-1R with IMC-A12 may 
have the potential to control metastasis in uveal mela-
noma patients. We found IMC-A12 to be effective in tar-
get inhibition, in blocking IGF-1R dependent signaling 
and cell migration in multiple UM cells that we tested.
Patients and methods
Patient eligibility
Patients with history of uveal melanoma and histologi-
cally confirmed metastatic disease. Patients were required 
to be at least 17 years old, have an Eastern Cooperative 
Oncology Group performance status of 0–2, life expec-
tancy of at least three months, at least one measurable 
lesion >10 mm according Response Evaluation Criteria in 
Solid Tumors (RECIST v1.1). Laboratory values within 
the prespecified range for absolute neutrophil count 
(≥1500/mm3), platelets (≥100 000/mm3), hemoglobin 
(≥90 g/L), serum creatinine (≤1.5 X institutional ULN), 
serum total bilirubin (≤1.5 X institutional ULN), aspartate 
and alanine aminotransferases (≤3 × ULN or ≤5 × ULN 
for patients with liver metastases), and fasting serum glu-
cose (<120 mg/dL). Patients had a washout period of at 
least six weeks between the last dose of the most recent 
prior immunotherapy, cytokine, biologic vaccine therapy, 
tumor embolization, and four weeks from prior radiother-
apy or chemotherapy. We excluded patients with sympto-
matic brain metastasis requiring steroids, leptomeningeal 
disease, ascites, pleural/pericardial effusions, carcino-
matous lymphangitis, Gilbert syndrome, HIV-positive 
patients with an absolute CD4 count <300 K/uL, patients 
with other active neoplasia, pregnant women, patients 
with serious active infections, and patients with a history 
of treatment with other agents targeting the IGF path-
way. Patients with a history of allergic reactions attributed 
to compounds of similar chemical or biologic composition 
to IMC-A12 were also excluded.
The study protocol was conducted at MD Anderson 
and approved by the MD Anderson Cancer Center 
Institutional Review Board. Furthermore, the study was 
done in accordance with the Declaration of Helsinki 
and International Conference of Harmonization Good 
Clinical Practice. Informed consent was obtained from all 
subjects before enrollment.
Study design and treatment
In this open-label Phase II trial enrolled patients were 
assigned to receive 10 mg/kg IV infusion over 1 hour every 
two weeks with treatment cycle defined as four weeks. 
Dose reduction was allowed according to protocol. Patients 
continued treatment until disease progression, unmanage-
able toxicity, termination of study, or death. We did disease 
assessment scans at baseline and then every eight weeks 
until discontinuation of study treatment. Response and 
progression were evaluated using the new international 
criteria proposed by the RECIST criteria (version 1.1). 
We used the National Cancer Institute Common Toxicity 
Criteria (CTCAE version 4.0) to grade adverse events. 
The primary endpoint of the study was investigator-as-
sessed objective response rate (proportion of patients with 
complete or partial response). Secondary endpoints were 
to determine the disease control rate (the proportion of 
subjects with a confirmed complete or partial response of 
any duration or stable disease ≥3 months in duration), pro-
gression-free survival (PFS), and overall survival (OS).
Statistical analysis
A Simon minimax two-stage design was used to assess 
the primary endpoint of response rate using RECIST 
1.0. Based on 90% power and an alpha level of 0.1 and 
assuming a clinically uninteresting response rate of 5% 
(null hypothesis H0: P ≤ 5%) and a target response rate of 
at least 20% (alternative hypothesis Ha: P ≥ 20%), a total 
of 32 evaluable subjects (defined as those subjects who 
received at least one dose of protocol therapy and had at 
least one post-treatment assessment of target and non-
target lesions) was planned. In Stage 1, 18 evaluable sub-
jects were planned. If at least one response is observed 
in Stage 1, enrollment in Stage 2 will be initiated. If no 
response is observed in Stage 1 after observing the last 
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enrolled subject for a minimum of four cycles, enroll-
ment will be stopped. In Stage 2, 14 additional evaluable 
subjects will be enrolled. If at least four responses are 
observed among the total number of evaluable subjects 
enrolled in Stages 1 and 2 combined, the null hypothesis 
will be rejected. If three or fewer responses are observed 
among the total number of evaluable subjects enrolled in 
Stages 1 and 2 combined, the null hypothesis will not be 
rejected.
In addition, baseline IGF-1R expression via immuno-
histochemistry was evaluated for correlation to response 
after the first 6–7 patients treated. This analysis was 
planned so as to inform conduct of the remainder of the 
trial and provide for a possible enrichment strategy.
The intent-to-treat population was defined as all sub-
jects registered in the study. The safety population was 
defined as all subjects who received any amount of pro-
tocol therapy in the study. PFS and OS were computed 
using the methods of Kaplan–Meier.
Western blot
Cells were lysed in a buffer containing 50 mmol/l Tris 
(pH 7.9), 150 mmol/l NaCl, 1% NP40, 1 mmol/l EDTA, 
10% glycerol, 1 mmol/l sodium vanadate, and protease 
inhibitor cocktail (Roche Pharmaceuticals, Nutley, New 
Jersey). Proteins were separated by SDS-PAGE with 
4–20% gradient gels (Bio-Rad Laboratories, Hercules, 
California), transferred to a Hybond-ECL nitrocellu-
lose membrane (GE Healthcare Biosciences, Piscataway, 
New Jersey), and blocked in 5% dry milk in PBS. The 
membrane was then incubated with primary and second-
ary antibodies, and target proteins were detected with 
ECL detection reagent (GE Healthcare Biosciences).
Cell migration assay
Assays for uveal melanoma cell migration were performed 
in Boyden chambers using uncoated filters (BD Biocoat 
control 5inserts, BD Biocoat, San Jose, California). A 2.5 
× 10 cells/well were plated in serum-free medium, with 
or without a 6-hour treatment of 50 ug/mL IMC-A12, and 
the migration assay performed [13]. Stained cells were 
photographed with a Nikon Eclipse TE2000-U micro-
scope at ×20 magnification using NIS Elements advanced 
research software.
Immunohistochemistry technique and evaluation
Histopathological review and immunohistochemical 
stain for IGF-1R [IGF-1Rα Antibody (N-20): sc-712, 
Santa Cruz Biotechnology, Dallas] using a 1:1000 dilu-
tion. Paraffin sections of 4 μm were deparaffinized, 
rehydrated, and rinsed. After rinsing, the endogenous 
peroxidase activity was blocked by treatment with 0.5% 
hydrogen peroxide for 30 minutes. The sections were 
then rinsed and incubated with blocking serum (1% 
BSA) for 20 minutes. The IGF-1Rα antibody was applied 
and incubated overnight at +8° Celsius. A biotinylated 
anti-rabbit antibody immunoglobulin G was applied as 
a secondary antibody and incubated for 30 minutes and 
then rinsed and the avidin-biotin complex incubated for 
another 30 minutes. The peroxide reaction was devel-
oped using 3,3′-diaminobenzidine tetrahydrochloride 
(0.6 mg/mL with 0.03% hydrogen peroxide) for 6 min-
utes. Counterstaining was performed by Mayer’s hema-
toxylin. Tris-buffered saline (pH 7.6) was used for rinsing 
between the different steps. Normal placenta tissue was 
used for positive controls [4,11,14].
Results
Effect of IMC-A12 on UM cells
In an attempt to characterize the effect of IMC-A12 in 
vitro, we tested the effect of this IGF-1R blocking anti-
body on inhibition of target activation, downstream signa-
ling, and cell migration of UM cells. First, we determined 
the expression levels of the target IGF-1R in a panel of 
UM cell lines with different genetic background[15,16] 
and found all of them to express the IGF-1R (Fig. 1a). 
When UM cell lines from this panel were treated with 
IMC-A12, complete inhibition of IGF-1R phosphoryla-
tion/activation was observed at 50 ug/mL IMC-A12 con-
centration and within 6-hour treatment period (Fig.  1b 
and c). On testing the effects of IMC-A12 on downstream 
effectors of IGF-1 signaling, we observed efficient inhi-
bition of Akt and Erk1/2 activation in UM cells (Fig. 1d). 
Interestingly, testing this antibody in an in vitro cell 
migration assay with UM cells and 10% FBS as chemo-at-
tractant showed differential effects of IMC-A12 in block-
ing cell migration based on the cell line tested (Fig. 1e). 
A possible explanation of this selectivity may be due to 
difference in migration potential of these cell lines used, 
with cell line 92.1 being highly migratory as observed in 
upper-middle panel of Fig. 1e as compared to consider-
ably lower migration potential of OMM1(lower middle 
panel of Fig. 1e).
Patient characteristics
Between 8 May 2011 and 4 January 2013, 18 patients 
were enrolled at two separate institutions. The clin-
ical characteristics of these patients are described in 
(Table 1). The median age was 64 years (range 26–85), 
and 56% of the study population was male. One patient 
had type II diabetes mellitus, and one patient had predi-
abetes before starting the clinical study. The majority of 
patients had received 0–1 prior therapies for metastatic 
uveal melanoma.
Toxicity
Adverse events of any grade occurred in 13 of 18 patients 
(72.2%). The most common adverse events considered 
related to treatment were constitutional symptoms such 
as fatigue (50%) and weight loss (39%) followed by lab-
oratory changes of hyperglycemia (28%) and increased 
aspartate aminotransferase (28%). Treatment-related 
grade 3 adverse events were rare and occurred in one 
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patient (5%) each including anorexia, diarrhea, hyperten-
sion, dehydration and increased lipase, cholesterol, and 
triglycerides. There were no grade 4 or 5 related adverse 
events. A list of treatment-related adverse events occur-
ring in more than one is presented in Table 2.
Efficacy
The median follow-up period was 20 weeks. Of 18 
patients treated with IMC-A12, 10 patients (55%) had 
stable disease as best response, seven patients (38%) had 
progression of disease, and one patient (6%) was not eval-
uable for response due to death prior to follow-up scans. 
No partial response or complete response was observed, 
however, the disease control rate, defined as complete 
response + partial response + stable disease ≥3 months, 
was 50%. All patients were evaluable for PFS and OS 
analyses. At the time of data analysis, all patients had 
died. Median PFS was 3.1 months (Fig. 2), and median 
OS was 13.8 months (Fig. 3).
Immunohistochemistry for IGF-1R
Baseline metastatic tumor samples were received for 17 
patients. Adequate tumor tissue for IGF-1R expression 
was available in 15 of the 17 cases. Cases were reviewed 
by a pathologist and scored according to the following 
percentage of tumor positive for IGF-1R: 1– <33% = 
1; 33–<67% = 2; and 67–100% = 3. There was no base-
line IGF-1R expression in seven cases (47%); four cases 
(27%) had a baseline score of 1, while two cases (13%) 
had a score of 2, and another two (13%) cases had a base-
line IGF-1R score of 3.
Discussion
The IGF pathway is one of many targetable pathways 
activated in metastatic uveal melanoma. Our study had no 
clinical responses to single-agent IMC-A12 and a disease 
control rate of 50%, suggesting half the patients expe-
rienced stable disease for at least three months, which 
was prespecified secondary endpoint per study protocol. 
However, the median PFS of 3.1 months fails to trans-
late this therapy into a meaningful outcome. One reason 
for lack of observed clinical activity of IMC-A12 may be 
related to low or absent IGF-1R expression in the study 
population. Nearly 75% of the baseline tissues analyzed 
had absent or 0–<33% tumor expression of IGF-1R. 
The lack of a highly expressed target is directly related 
to the lack of efficacy. Additionally, because of the com-
plex nature of signaling networks in uveal melanoma, it is 
Fig. 1
Insulin-like growth factor type I receptor (IGF-1R) expression and effect of IMC-A12 in UM cells. (a) IGF-1R protein levels in a panel of UM 
cells. (b) IMC-A12 inhibits IGF-1R activation in UM cells: IMC-A12 dose response in UM cells showing inhibition of IGF-1R phosphorylation on 
treatment of OCM1 and MEL270 with increasing concentration of the agent. (c) Time course of IMC-A12 mediated IGF-1R inhibition: 50 ug/mL 
IMC-A12 can completely inhibit IGF-1R phosphorylation post 6 h treatment in vitro. (d) IMC-A12 inhibits IGF-1R dependent signaling in UM cells: 
A treatment with 50 ug/mL IMC-A12 inhibited Akt and Erk1/2 activation in UM cells post 6 h treatment. (e) IMC-A12 inhibits UM cell migration in 
an in vitro cell migration assay: 50 ug/mL IMC-A12 inhibited cell migration in 92.1 and OMM1 cells on overnight treatment.
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unlikely that a single targeted agent will be able to provide 
enough growth inhibition to withstand compensatory sign-
aling cascades. Notably, however, IMC-A12 was minimally 
toxic, with no grade 4 treatment-related adverse events, and 
low frequency of grade 3 events occurring in one patient 
each. The patient diagnosed with type II diabetes melli-
tus was taking glimepiride before starting the protocol. It 
was not necessary to add any new medication for his dia-
betes. Compensatory pathways are known to be activated 
Table 1 Patients’ characteristics
Characteristic No. of patients (%), n = 18
Median age (range), y 64 (range 26–85)
Gender
 Male 10 (56)
 Female 8 (44)
ECOG performance status
 0 10 (56)
 1 3 (17)
 2 1 (5)
 Unknown 4 (22)
Past medical history of prediabetes or diabetes
 Prediabetes 1 (5)
 Diabetes 1 (5)
Sites of metastasis
 Liver only 6 (33)
 Liver and other sites 9 (50)
  Lung 7 (39)
  Bone 5 (28)
  Pleura 2 (11)
  Lymph nodes 2 (11)
  Adrenal glands 2 (11)
  Peritoneal 2 (11)
  Subcutis 2 (11)
  Deep soft tissue 2 (11)
  Pancreas 1 (5)
  Portal vein 1 (5)
  Kidney 1 (5)
  Bladder 1 (5)
 Other sites only 3 (17)
  Lung (bilateral) 2 (11)
  Spleen 1 (5)
Prior therapy for metastatic disease
 0 7 (39)
 1 8 (44)
 2 1 (5)
 3+ 2 (11)
ECOG, Eastern Cooperative Oncology Group.
Table 2 Treatment-related adverse events occurring in more than 
one patient
Adverse events Grade 1–2 (%) Grade 3 (%)
Anemia 2 (11.1) 0
Anorexia 2 (11.1) 1 (5.5)
Telangiectasia 2 (11.1) 0
Skin and subcutaneous disorders 2 (11.1) 0
Headache 2 (11.1) 0
Paresthesia 2 (11.1) 0
Hyperkalemia 2 (11.1) 0
Hypocalcemia 2 (11.1) 0
Hyperuricemia 2 (11.1) 0
ALT increased 2 (11.1) 0
Thrombocytopenia 3 (16.6) 0
Pruritus 3 (16.6) 0
Amylase increased 3 (16.6) 0
High cholesterol 3 (16.6) 1 (5.5)
Rash 4 (22.2) 0
Dry skin 4 (22.2) 0
Nausea 4 (22.2) 0
Diarrhea 4 (22.2) 1 (5.5)
Lipase increased 4 (22.2) 1 (5.5)
Hypertriglyceridemia 4 (22.2) 1 (5.5)
Hyperglycemia 5 (27.7) 0
AST increased 5 (27.7) 0
Weight loss 7 (38.8) 0
Fatigue 9 (50.0) 0
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Fig. 2
Represents a Kaplan–Meier plot of progression-free survival (PFS). 
The median PFS was 3.1 months.
Fig. 3
Represents a Kaplan–Meier plot of overall survival (OS). The median 
OS was 13.8 months.
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in uveal melanoma, including HGF-c-Met, SRC, Ras, 
EGFR, VEGF, and phosphatidylinositol-3-kinase-AKT 
signaling. Moving forward, IGF pathway inhibition owing 
to its low toxicity profile could be studied in combination 
with other pathway-specific agents using baseline IGF-1R 
expression as an entry criterion, and on-treatment biopsies 
to determine the amount of target saturation or receptor 
occupancy taking place. To date, there are no single-agent 
therapies with meaningful efficacy in metastatic uveal 
melanoma. Well-designed combination trials with correla-
tive studies are needed to fill this knowledge gap.
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